secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001213900-23-084317
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar reports Q3 net loss $45.8M, cash $372.7M; Phase 2b atopic derm study initiated
--------------------------------------------------------------------------------

- Net loss $45.8M ($0.24/shr) vs $59.0M y/y; non-GAAP loss $35.7M ($0.19/shr).
- Revenue $24.1M, slightly up from $23.6M y/y; cash $372.7M, down from $505.0M at year-end.
- Initiated Phase 2b study of rezpegaldesleukin in atopic dermatitis (Oct 2023); Phase 2b alopecia areata to start early 2024.
- Clinical collaboration with CBMG to evaluate NKTR-255 in combination with TIL therapy in NSCLC.
- R&D expense reduced to $24.1M (Q3) due to wind-down of bempegaldesleukin program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390023084317/0001213900-23-084317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390023084317/ea187824-8k_nektarther.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-084317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer